88 FR 3406
EPA announced the availability of and seeks comment on a draft white paper entitled “Availability of New Approach Methodologies (NAMs) in the Endocrine Disruptor Screening Program (EDSP),” developed pursuant to the Federal, Food, Drug and Cosmetic Act, which requires the Agency to develop a screening program, to determine whether certain substances may have an effect in humans that is similar to an effect produced by a naturally occurring estrogen, or other endocrine effects.